Latham & Watkins advises Performance Livestock Analytics in funding and separation from Zoetis. Performance Livestock Analytics (PLA), an independent precision livestock platform using cattle data and...
Performance Livestock Analytics’ Funding Round Led By Builders VC
Endava’s Acquisition of TLM
Latham & Watkins Advises TLM in Acquisition by Endava. Endava, a global provider of digital transformation, agile development and intelligent automation services, acquired TLM Partners, Inc...
Yield Engineering Systems’ $55 Million IP-Backed Financing from Aon
Latham & Watkins advised YES on the transaction. Yield Engineering Systems (YES) has announced a $55 million IP-backed financing from a fund managed by Aon Advantage...
Tipalti’s $150 Million Growth Financing
Latham & Watkins and Gornitzky & Co. advise Hercules on the financing. Tipalti announced it has raised $150 million in incremental growth financing from JPMorgan Chase...
Alphatec Spine’s $200 Million Growth Financing Facilities
Latham & Watkins LLP represented Alphatec in the transactions. Alphatec Holdings, Inc. (Nasdaq: ATEC), a medical technology company focusing on surgical treatment for spinal disorders has...
Tricida’s $125 Million Debt Facility
Latham & Watkins LLP represented Hercules in the transaction. Tricida, Inc. (Nasdaq: TCDA) has entered into a debt facility with Hercules Capital, Inc. (NYSE: HTGC), a...
Alphatec Spine’s $50 Million Revolving Credit Facility
Latham & Watkins represented Alphatec in the transaction. Alphatec Holdings, Inc. (Alphatec) announced the close of an asset-based revolving credit facility in the maximum aggregate amount...
Alignment Healthcare’ $250 Million Debt Financing
Latham & Watkins represented Alignment Healthcare in the transaction. Alignment Healthcare, Inc.(Alignment Healthcare) (NASDAQ: ALHC), a leading tech-enabled MedicareAdvantage company, has announced the close of an...
BridgeBio Pharma’s Credit Facility Amendment
Latham & Watkins advised BridgeBio on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, has entered into...
Innocoll Biotherapeutics’ $125 Million Term Loan Facility
Latham & Watkins represented Innocoll Biotherapeutics in the transaction. Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, has announced the successful...
BridgeBio Pharma’s $750 Million Non-Dilutive Debt Financing
Latham & Watkins represented BridgeBio in the transaction. BridgeBio Pharma (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, executed a...
Tailwind Two Acquisition Corp.’s $1.58 Billion Combination with Terran Orbital Corporation
Kirkland & Ellis advised Tailwind Two and Akin Gump Strauss Hauer & Feld advised Terran Orbital on the deal. Latham & Watkins represented Francisco Partners. Tailwind...